



1642  
#8  
JM  
3/12/03

**PATENT**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

INTERNATIONAL APPLICATION OF : Toshihiko Yanagita

FOR : **DRUG FOR INHIBITING MYOMETRIAL CONTRACTION**

SERIAL NO. : 10/030,298

FILED : December 21, 2002

EXAMINER : Unknown

ART UNIT : 1642

ATTORNEY DOCKET NO. : **TECH CENTER 1600/2900** YAMZ 2 00014

March 7, 2003  
Cleveland, OH 44114-2579

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. § 1.56, 1.97, 1.98 and MPEP § 609, applicant submits the following Disclosure Statement concerning art of which the applicant is aware. A copy of PTO-1449 is enclosed herewith.

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein or submitted herewith is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

**CERTIFICATE OF MAILING**

I hereby certify that this **INFORMATION DISCLOSURE STATEMENT** is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231, on March 7, 2003.

By: *Lynnda S. Kalembe*  
Lynnda S. Kalembe

Under § 1.98(a)(3), no concise explanation of relevance is required for information that is in the English language. Accordingly, the enclosed patent requires no further explanation (or no translation is available).

Consideration of the appropriate paragraph(s) indicated below is respectfully requested:

☐ **WITHIN THREE MONTHS OF FILING:** Under § 1.97(b)(1), this information disclosure statement is being filed within three months of the filing date of the application. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

☒ **BEFORE FIRST OFFICE ACTION:** Under § 1.97(b)(3), this information disclosure statement is being filed before the mailing date of a first Office Action on the merits. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

☒ **FOREIGN SEARCH REPORT:** Under § 1.97(e)(1), the undersigned certifies that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. Although it is believed no fee is necessary, any deficiency in fees should be charged to Deposit Account No. 06-0308.

It is respectfully requested that the attached document(s) be considered and officially cited in examination of this application.

Respectfully submitted,

FAY, SHARPE, FAGAN,  
MINNICH & McKEE, LLP



Richard M. Klein  
Reg. No.33,000  
1100 Superior Avenue, Seventh Floor  
Cleveland, Ohio 44114-2518  
(216) 861-5582



Subst. Form PTO-1449		Atty.Dkt.No: YAMZ 2 00014		Serial No.: 10/030,298	
APPLICANT'S(S') INFORMATION DISCLOSURE STATEMENT		Applicant(s): Toshihiko Yanagita			
		Filing Date: December 21, 2001		Group: 1642	
<b>U.S. PATENT DOCUMENTS</b>					
Initial *		Document No.	Date	Name	Class Subcl. Filing Date
	AA	5,910,482	08 JUN 1999	Yallampalli et al.	514 12 19 MAR 1996
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
<b>FOREIGN PATENT DOCUMENTS</b>					
		Document No.	Date	Country	Class Subcl. Translation?
	AH	0 622 458 A2	02 NOV 1994	EPO	
	AJ				
	AK				
	AL				
	AM				
	AN				
<b>OTHER ART</b>					
	AO	MICHISHITA M., ET AL., "Expression of adrenomedullin in the endometrium of the human uterus." <i>Obstetrics &amp; Gynecology</i> , vol. 93, no. 1, January 1999 (1999-01), pages 66-70			
	AP	EGUCHI S., ET AL., "Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells," <i>Endocrinology</i> , Baltimore, MD, vol. 135, no. 6, 1994, pages 2454-2458			
Examiner:				Date Considered:	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.					

RECEIVED  
MAR 14 2003  
TECH CENTER 1600/2900